Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia

NCT00268697 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00268697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00268697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
January 31, 2007
Enrollment
1,267 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia